Issue: #7May 2012


In Remembrance: Charles "Chuck" Beard 

- Visit Adesis at Bio 2012 Boston-Now Scheduling Meetings

- New Compounds for May- Always In Stock!



In This Issue
In Remembrance
BIO - Boston
Compounds of the Month
May Promotion


catalog e-news



join mailing list

Join Our List

Join Our Mailing List

Adesis Whitepaper

oct poster

Efficient Methods for Regioselective 

Functionalization of 

6-Substituted Furo[3,2-b] pyridines for Indole Isosteres.  



Quick Links








In Remembrance:

Charles "Chuck" Beard



It is with regret that we announce the death of Charles D. Beard, who passed away on April 6, 2012.  Charles 'Chuck' Beard was a visionary and pioneer in creating CB Research and Development, Inc. (CBRD, 1991), which provided contract chemistry services for biomaterials and pharmaceutical research and development.  This was a decade before the age of strategic research outsourcing was in vogue.  In 2005, CBRD was transformed into Adesis, which offered expanded research services to various private and governmental research organizations in the life sciences.


Dr. Beard received his BS and Ph.D. from the University of Richmond and University of Pennsylvania, respectively, and held postdoctoral fellowships at Ohio State University and the University of California Medical Center at San Francisco. He subsequently held positions of increasing responsibility at Fluorochem, Inc., Union Carbide, Hughes Aircraft, and J&J, prior to the creation of CB Research and Development and later Adesis, Inc.


Dr. Beard pioneered the translation of academic chemical research into high-value commercialization, especially in the realm of materials and biomaterials research for medical applications and the defense industry.  Some of his early advances, for space applications, included new energetic materials for propellants, inorganic polymers for high-temperature aviation applications, and monomers for electronic applications. 


At Johnson & Johnson, he worked on specialized monomers for ophthalmology applications of UV-protective intraocular lenses (IOLs) and absorbable sutures. These items are used by millions of patients, with significant improvements in their quality of life.


His entrepreneurial spirit went beyond traditional chemistry pursuits, as demonstrated by the creation of the Catalog of Advanced Heterocyclic Intermediates in 1999.  This initiative arose from his recognition that there were unmet needs in orthogonally-functionalized azoles for research.


The Adesis community and clients will miss Chuck's laser-like attention to technical details and experimentation.  His strong moral principles, entrepreneurship, and work ethic will continue into the future as hallmarks of Adesis.



2012 BIO International Convention - Boston


2012 Bio - Boston - June 18-21, 2012 

schedule a meeting prior to the show Schedule Meeting


Compounds of the Month

New Heterocyclic Intermediates 

We have recently introduced new furopyridines, azaindoles, pyrido-dioxanes, and dihydro-pyranopyridines into our catalog.  Below are the first examples to reach inventory.  Check back regularly as we expand the range of substitution.  Be sure to explore all our imidazo-pyridines and other novel heterocycles, too.  




To see all of our new heterocycles Click here 




About Adesis

Adesis, Inc. is a contract research organization (CRO) supporting the pharmaceutical and biopharmaceutical industry, biomaterials and catalysts industry. 


The life science industry has embraced the philosophy of outsourcing reference standards (competitor's drugs), targets, scaffolds, building blocks and advanced intermediates. Outsourcing allows medicinal chemists to focus on design and assembly of new targets for pharmacological evaluation and streamlines the early stage drug discovery process. Similarly, other chemistry-based research organizations (catalysts, biomaterials and fragrances) have accepted similar modus of operendi in order to maximize cost controls, while having timely project successes.


The core foundation of Adesis, Inc. is attributed to our experienced chemists with the expertise to conduct complex multi-step synthetic sequences (typical range of 2 - 25 steps).



15% Off Any 1 Gram Order

May Promotion: 

15% of any 1 gram catalog order.


Please call Jack Church to place your order: 302-323-6305 or email

Offer Expires: June 15th 2012 
Only one offer per person 

We hope you have enjoyed reading our Adesis newsletter.  We welcome your comments.



If you are interested in how your company or institution can do business with Adesis or to learn more about our capabilities, please contact one of the members of our business development team.




Ronald G. Yarger, PhD

Director, Business Development 

Ph. 302-261-3383; Mobile 302-358-8837 



Paul Beard, MBA BS 

Business Development Associate 

Ph. 302-323-6314; Mobile 302-383-5918